摘要
Contrave是FDA新批准的用于肥胖患者减肥的口服缓释药物,是由2种药物成分纳曲酮和安非他酮组合而成,每片包含盐酸纳曲酮8 mg、盐酸安非他酮90 mg,2者合用对激动阿片促黑激素皮质素原(pro-opiomelanocortin,POMC)神经元具有互补和协同效应,能显著减轻肥胖患者体质量,并且无严重不良事件报道。本文对Contrave的临床前研究、临床试验、药代动力学以及不良反应等方面作一综述。
Contrave is approved by FDA as an oral extended-release drug used in obese patients' weight loss. Each tablet contains 8 mg of naltrexone hydrochloride and 90 mg of bupropion hydrochloride. And BUP + NAL stimulated hypothalamic pro-opiomelanocortin( POMC) neurons with a complementary and synergy effect. Contrave could reduce obese patients' body weight and has no serious adverse events. Contrave preclinical studies,clinical research,pharmacokinetics characteristics,adverse reactions are summaried in the article.
出处
《中国生化药物杂志》
CAS
2016年第1期183-185,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
Contrave
肥胖
临床前研究
临床试验
药代动力学
不良反应
Contrave
obesity
preclinical studies
clinical trail
pharmacokinetics characteristics
adverse reactions